Clinuvel Pharmaceuticals Limited
ASX: CUV
Steady SCENESSE expansion and strong cash reserves underpin CUV’s earnings stability.
(Source: TradingView) 3-Month Performance Profile of CUV on a DTF compared to S&P/ASX 200 (XJO).
CUV reported net income of $36.17 million in FY2025, a modest 1.5% YoY increase, supported by disciplined operations and steady product performance. Cash reserves rose 2
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
